BioAge Labs, Inc. (BIOA): Results of Operations and Financial Condition
BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in th
How this was made
The 30-second read
Why it matters
This 8-K combines Q2 financials with operational milestones for BGE-102, including first dosing in QUELL-CV and planned initiation of QUELL-DME, plus a cash runway estimate through 2029.
Market read
Traders may reassess near-term expectations for BGE-102’s Phase 2 dose-response readout timing and the sustainability of the company’s burn rate given the updated cash runway.
What to watch
R&D expense rose due to QUELL-CV start-up and planned QUELL-DME initiation, which could pressure sentiment if burn rate accelerates faster than expected despite the stated cash runway.
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
BioAge advanced BGE-102 into Phase 2 and reported a substantial cash position, while research and development expense and net loss increased from the prior-year period.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenueother | $2.4 million | – | – |
| Research and development expensesother | $24.4 million | – | $4.6 million increase |
| General and administrative expensesother | $7.4 million | – | $0.1 million increase |
| Net lossother | $26.1 million | – | – |
| Net loss per weighted-average common share outstanding, basic and dilutedother | $0.58 per weighted-average common share outstanding, basic and diluted | – | – |
second half of 2026; mid-2026; mid-2027; by year-end 2026; through 2029 outlook
- Notetopline data anticipated in the second half of 2026
- NoteThe Company plans to initiate QUELL-DME, a Phase 1b/2a proof-of-concept trial of BGE-102 in patients with diabetic macular edema, in mid-2026; results are anticipated in mid-2027.
- NoteThe Company intends to file its first IND for an APJ program by year-end 2026.
- NoteBased on the Company’s current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.
What drove it
- In June 2026, BioAge announced that the first participant was dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102, its oral, brain-penetrant NLRP3 inhibitor, measuring inflammatory and cardiometabolic biomarkers.
- QUELL-CV is a randomized, double-blind, placebo-controlled trial evaluating three once-daily oral doses of BGE-102 (30 mg, 60 mg, and 90 mg) against placebo in approximately 160 adults with obesity and elevated baseline inflammation.
- The primary endpoint is percent change from baseline in hsCRP, a pharmacodynamic measure of NLRP3 pathway inhibition, over 12 weeks of dosing.
- BGE-102 achieved up to 98% suppression of IL-1β at trough in an ex vivo whole-blood assay, along with median hsCRP reductions of 86% from baseline at both 60 mg and 120 mg once daily.
- BGE-102 was well tolerated across all dose levels evaluated, with no serious adverse events, no treatment-emergent adverse events leading to discontinuation, and no clinically meaningful changes in vital signs, ECGs, or laboratory values.
- The $4.6 million increase in research and development expenses was primarily attributable to a $7.9 million increase in direct costs related to BioAge’s BGE-102 program associated with the initiation of QUELL-CV, start-up costs related to the planned initiation of QUELL-DME, licensing fees, and drug-product manufacturing.
- The research and development expense increase was further driven by a $1.5 million increase in personnel-related expenses and a $0.3 million increase in allocated facility and other expenses, partially offset by a $3.3 million decrease in direct costs for other programs and a $1.9 million decrease in azelaprag direct costs following termination of its development in January 2025.
- BioAge's multi-year research collaboration with Novartis continued to advance, with multiple targets under evaluation, and the Company continued to progress its strategic collaboration with Lilly ExploR&D.
Concerns
- Net loss was $26.1 million for the quarter ended June 30, 2026, compared to a net loss of $21.6 million for the same period in 2025.
- Research and development expenses were $24.4 million for the quarter ended June 30, 2026, compared to $19.8 million for the same period in 2025.
- QUELL-DME remains planned to initiate in mid-2026, with results anticipated in mid-2027.
- The filing identifies risks associated with clinical trials, including the ability to adequately manage clinical activities for BGE-102 and APJ programs, and unexpected concerns that may arise from additional data or analysis obtained during clinical trials.
What to watch
- Topline QUELL-CV data anticipated in the second half of 2026.
- Initiation of QUELL-DME in mid-2026 and results anticipated in mid-2027.
- The Company’s intended filing of its first IND for an APJ program by year-end 2026.
- Dose selection for further BGE-102 development from the QUELL-CV dose-response characterization.
Balance sheet and cash flow
- As of June 30, 2026, BioAge had approximately $381.3 million in cash, cash equivalents, and marketable securities.
- Based on the Company’s current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.
Analysis
BioAge reported collaboration revenue of $2.4 million for each of the quarters ended June 30, 2026 and 2025. The company remains a clinical-stage biopharmaceutical business, and the release centered on development progress rather than commercial revenue growth. Its principal advance was dosing the first participant in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 in approximately 160 adults with obesity and elevated baseline inflammation.
Development spending increased as BGE-102 moved into broader clinical execution. Research and development expenses were $24.4 million, compared with $19.8 million in the prior-year period, with the stated increase primarily tied to BGE-102 direct costs, including QUELL-CV initiation, QUELL-DME start-up costs, licensing fees, and drug-product manufacturing. The company also cited higher personnel-related and allocated facility costs. These increases were partly offset by lower direct costs for other programs and lower azelaprag direct costs following termination of that development program in January 2025.
General and administrative expenses were $7.4 million, compared with $7.3 million in the prior-year period. Net loss was $26.1 million, compared with $21.6 million, while net loss per weighted-average common share outstanding, basic and diluted, was $0.58 compared with $0.60. The reported loss expansion coincided with increased BGE-102 investment and did not reflect a change in reported collaboration revenue.
The clinical data and milestones are the central operating focus. BioAge stated that Phase 1 BGE-102 data showed up to 98% suppression of IL-1β at trough and median hsCRP reductions of 86% from baseline at both 60 mg and 120 mg once daily. QUELL-CV is evaluating 30 mg, 60 mg, and 90 mg once-daily doses against placebo, with percent change from baseline in hsCRP over 12 weeks as the primary endpoint. Topline data are anticipated in the second half of 2026, making this readout the near-term clinical catalyst identified in the filing.
Liquidity supports the planned development schedule. BioAge had approximately $381.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, and estimated those resources would fund operations and capital expenses through 2029. The company also plans to initiate QUELL-DME in mid-2026, expects results in mid-2027, and intends to file its first IND for an APJ program by year-end 2026. Execution against these milestones, particularly the QUELL-CV readout and BGE-102 dose selection, will determine the next stage of pipeline development.
Management, verbatim
Our Phase 1 data show that BGE-102 is a potential best-in-class NLRP3 inhibitor: a well-tolerated once-daily pill that delivered up to 98% suppression of IL-1β and brought hsCRP down to normal levels in most participants. We have dosed the first participant in QUELL-CV, our Phase 2 trial in patients with obesity and inflammation at elevated cardiovascular risk, with topline data anticipated in the second half of 2026. We also plan to start a second proof-of-concept trial this year in diabetic macular edema. These studies will test the broad potential of NLRP3 inhibition across inflammasome-driven diseases, and we are actively evaluating additional indications where this mechanism can deliver meaningful benefit. With a strong cash position, we are well positioned to advance BGE-102 across multiple opportunities and continue progressing the broader BioAge pipeline.
Kristen Fortney, Ph.D., CEO and co-founder of BioAge
Not in the filing
stated, not guessed- Total revenue
- Revenue by operating segment
- Gross profit
- Gross margin
- Operating income or loss
- Income tax expense or benefit
- Tax rate
- Non-GAAP financial measures
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt
- Share repurchases
- Dividends
- Prior-quarter comparisons for reported financial metrics
- Financial revenue, gross margin, operating expense, or tax-rate guidance
- Prior outlook for comparison with reported results
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BioAge is a clinical-stage biopharma developing BGE-102, an oral, brain-penetrant NLRP3 inhibitor, with multiple inflammation-driven indications.
Ticker impact
BioAge filed an 8-K with Q2 results plus updates that the first QUELL-CV participant was dosed and topline data are expected in 2H 2026.
Moderate upside bias on any market read-through that QUELL-CV dosing and biomarker suppression remain on track; volatility likely around future topline timing.
The filing is a primary disclosure (8-K) with concrete trial initiation status, endpoint design, and cash runway through 2029, but it does not include new QUELL-CV efficacy results yet.
Market effects
Reinforces investor appetite for inflammasome/NLRP3-targeting programs and biomarker-driven Phase 2 dose-ranging strategies.
Limited, primarily US small-cap biotech sentiment.
Low, as updates are company-specific and not a cross-market regulatory or macro catalyst.
Counterpoint
The update highlights dosing and plans, not new QUELL-CV topline efficacy, so the market may already be pricing the next readout window.
Key entities
- issuerBioAge Labs, Inc.
Clinical-stage biopharmaceutical company filing Q2 2026 results and BGE-102 trial updates.
- product_candidateBGE-102
Oral, brain-penetrant NLRP3 inhibitor being advanced in QUELL-CV and QUELL-DME.
- clinical_trialQUELL-CV
Phase 2 dose-ranging proof-of-concept trial in obesity with elevated cardiovascular risk; primary endpoint is hsCRP change over 12 weeks.
- clinical_trialQUELL-DME
Planned Phase 1b/2a proof-of-concept trial in diabetic macular edema; results anticipated mid-2027.
- biological_targetNLRP3
Inflammasome component positioned as upstream driver of inflammatory cascade across diseases.
